Orasure Technologies Inc (OSUR)

$4.11

-0.36

(-8.05%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $4.11
    $4.50
    $4.11
    downward going graph

    0.0%

    Downside

    Day's Volatility :8.67%

    Upside

    8.67%

    downward going graph
  • $3.92
    $8.45
    $4.11
    downward going graph

    4.74%

    Downside

    52 Weeks Volatility :53.67%

    Upside

    51.36%

    downward going graph

Returns

PeriodOrasure Technologies IncSector (Health Care)Index (Russel 2000)
3 Months
-10.85%
5.1%
0.0%
6 Months
-43.15%
5.1%
0.0%
1 Year
-31.95%
16.6%
0.0%
3 Years
-62.6%
13.2%
-21.4%

Highlights

Market Capitalization
333.3M
Book Value
$5.71
Earnings Per Share (EPS)
0.36
PE Ratio
11.42
PEG Ratio
2.3
Wall Street Target Price
6.33
Profit Margin
9.88%
Operating Margin TTM
-0.06%
Return On Assets TTM
3.62%
Return On Equity TTM
6.59%
Revenue TTM
273.5M
Revenue Per Share TTM
3.71
Quarterly Revenue Growth YOY
-36.4%
Gross Profit TTM
147.6M
EBITDA
31.5M
Diluted Eps TTM
0.36
Quarterly Earnings Growth YOY
0.3
EPS Estimate Current Year
-0.19
EPS Estimate Next Year
-0.21
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    50%Buy
    50%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Orasure Technologies Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 54.01%

Current $4.11
Target $6.33

Company Financials

FY18Y/Y Change
Revenue
181.7M
↑ 8.79%
Net Income
20.4M
↓ 34.1%
Net Profit Margin
11.22%
↓ 7.3%
FY19Y/Y Change
Revenue
154.6M
↓ 14.93%
Net Income
16.7M
↓ 18.34%
Net Profit Margin
10.77%
↓ 0.45%
FY20Y/Y Change
Revenue
171.7M
↑ 11.07%
Net Income
-14.9M
↓ 189.59%
Net Profit Margin
-8.69%
↓ 19.46%
FY21Y/Y Change
Revenue
233.7M
↑ 36.08%
Net Income
-23.0M
↑ 54.12%
Net Profit Margin
-9.84%
↓ 1.15%
FY22Y/Y Change
Revenue
387.5M
↑ 65.82%
Net Income
-17.9M
↓ 22.01%
Net Profit Margin
-4.63%
↑ 5.21%
FY23Y/Y Change
Revenue
405.5M
↑ 4.64%
Net Income
53.7M
↓ 399.16%
Net Profit Margin
13.23%
↑ 17.86%
Q1 FY23Q/Q Change
Revenue
155.0M
↑ 25.91%
Net Income
27.2M
↑ 74.91%
Net Profit Margin
17.56%
↑ 4.92%
Q2 FY23Q/Q Change
Revenue
85.4M
↓ 44.86%
Net Income
-4.8M
↓ 117.62%
Net Profit Margin
-5.61%
↓ 23.17%
Q3 FY23Q/Q Change
Revenue
89.2M
↑ 4.38%
Net Income
11.2M
↓ 332.67%
Net Profit Margin
12.51%
↑ 18.12%
Q4 FY23Q/Q Change
Revenue
75.9M
↓ 14.92%
Net Income
20.1M
↑ 79.88%
Net Profit Margin
26.45%
↑ 13.94%
Q1 FY24Q/Q Change
Revenue
54.1M
↓ 28.66%
Net Income
-3.6M
↓ 117.85%
Net Profit Margin
-6.62%
↓ 33.07%
Q2 FY24Q/Q Change
Revenue
54.3M
↑ 0.38%
Net Income
-615.0K
↓ 82.84%
Net Profit Margin
-1.13%
↑ 5.49%
FY18Y/Y Change
Total Assets
315.6M
↑ 6.54%
Total Liabilities
32.2M
↓ 15.55%
FY19Y/Y Change
Total Assets
349.3M
↑ 10.69%
Total Liabilities
42.2M
↑ 30.93%
FY20Y/Y Change
Total Assets
454.5M
↑ 30.11%
Total Liabilities
55.9M
↑ 32.62%
FY21Y/Y Change
Total Assets
461.0M
↑ 1.43%
Total Liabilities
80.5M
↑ 43.93%
FY22Y/Y Change
Total Assets
444.7M
↓ 3.53%
Total Liabilities
81.1M
↑ 0.78%
FY23Y/Y Change
Total Assets
482.8M
↑ 8.58%
Total Liabilities
52.2M
↓ 35.65%
Q1 FY23Q/Q Change
Total Assets
459.4M
↑ 3.31%
Total Liabilities
65.2M
↓ 19.55%
Q2 FY23Q/Q Change
Total Assets
453.6M
↓ 1.27%
Total Liabilities
59.5M
↓ 8.86%
Q3 FY23Q/Q Change
Total Assets
458.4M
↑ 1.07%
Total Liabilities
16.8M
↓ 71.76%
Q4 FY23Q/Q Change
Total Assets
482.8M
↑ 5.33%
Total Liabilities
52.2M
↑ 210.74%
Q1 FY24Q/Q Change
Total Assets
467.6M
↓ 3.17%
Total Liabilities
41.3M
↓ 20.83%
Q2 FY24Q/Q Change
Total Assets
466.3M
↓ 0.26%
Total Liabilities
40.5M
↓ 1.95%
FY18Y/Y Change
Operating Cash Flow
39.1M
↑ 38.83%
Investing Cash Flow
-17.4M
↓ 81.91%
Financing Cash Flow
-1.9M
↓ 106.21%
FY19Y/Y Change
Operating Cash Flow
9.8M
↓ 74.92%
Investing Cash Flow
-19.8M
↑ 13.6%
Financing Cash Flow
-4.7M
↑ 147.59%
FY20Y/Y Change
Operating Cash Flow
5.8M
↓ 40.77%
Investing Cash Flow
-14.0M
↓ 29.14%
Financing Cash Flow
92.5M
↓ 2075.2%
FY21Y/Y Change
Operating Cash Flow
-35.4M
↓ 709.3%
Investing Cash Flow
-5.5M
↓ 60.79%
Financing Cash Flow
-2.8M
↓ 103.05%
FY22Y/Y Change
Operating Cash Flow
-47.2M
↑ 33.41%
Investing Cash Flow
21.1M
↓ 483.29%
Financing Cash Flow
-3.8M
↑ 35.89%
Q1 FY23Q/Q Change
Operating Cash Flow
6.0M
↓ 133.32%
Investing Cash Flow
1.0M
↓ 96.03%
Financing Cash Flow
-1.3M
↑ 66.17%
Q2 FY23Q/Q Change
Operating Cash Flow
57.3M
↑ 854.15%
Investing Cash Flow
37.2M
↑ 3556.99%
Financing Cash Flow
-632.0K
↓ 52.52%

Technicals Summary

Sell

Neutral

Buy

Orasure Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Orasure Technologies Inc
Orasure Technologies Inc
-10.46%
-43.15%
-31.95%
-62.6%
-41.54%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
1.77%
20.41%
58.21%
30.75%
184.98%
Resmed Inc.
Resmed Inc.
14.32%
29.95%
65.51%
-17.65%
81.24%
Becton, Dickinson And Company
Becton, Dickinson And Company
-0.73%
-3.01%
-12.78%
-11.49%
-9.75%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
1.44%
-17.19%
-24.4%
-36.55%
104.36%
Alcon Ag
Alcon Ag
2.46%
8.46%
15.06%
12.76%
61.54%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Orasure Technologies Inc
Orasure Technologies Inc
11.42
11.42
2.3
-0.19
0.07
0.04
NA
5.71
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
81.91
81.91
4.06
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
35.33
35.33
2.05
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
46.72
46.72
1.08
13.11
0.06
0.03
0.02
89.5
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.71
42.71
5.15
6.51
0.2
0.11
0.0
35.49
Alcon Ag
Alcon Ag
42.64
42.64
3.53
3.05
0.05
0.03
0.0
42.35
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Orasure Technologies Inc
Orasure Technologies Inc
Buy
$333.3M
-41.54%
11.42
9.88%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$169.4B
184.98%
81.91
27.65%
Resmed Inc.
Resmed Inc.
Buy
$36.0B
81.24%
35.33
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.4B
-9.75%
46.72
7.13%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$21.8B
104.36%
42.71
18.25%
Alcon Ag
Alcon Ag
Buy
$46.7B
61.54%
42.64
11.44%

Insights on Orasure Technologies Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 54.13M → 54.33M (in $), with an average increase of 0.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -3.58M → -615.0K (in $), with an average increase of 482.8% per quarter

  • Vs RMD

    In the last 1 year, Resmed Inc. has given 65.5% return, outperforming this stock by 97.5%

  • Vs ISRG

    In the last 3 years, Orasure Technologies Inc has experienced a drawdown of -62.6%, however Intuitive Surgical, Inc. resisted the overall trend and outperformed by 44.9%

Institutional Holdings

  • BlackRock Inc

    9.90%

  • Dimensional Fund Advisors, Inc.

    5.91%

  • Vanguard Group Inc

    5.73%

  • Camber Capital Management LLC

    5.70%

  • Neuberger Berman Group LLC

    5.44%

  • State Street Corporation

    4.24%

Company Information

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo

Organization
Orasure Technologies Inc
Employees
638
CEO
Ms. Carrie Eglinton Manner
Industry
Health Technology

Discover More

FAQs